Monoclonal antibodies targeting PD-1/PD-L1 and CTLA-4 have proven to be valuable tools for overcoming the inhibitory regulation of T-cell activation imposed by tumor cells or the tumor microenvironment (TME) [29]. Here, PDCD1 is linked to neoplasm.